|
|
|
|
XenoPort Reports Positive Results From A Phase 2 Trial Of Arbaclofen Placarbil In Spinal Cord Injury Patients
Also Included In: Clinical Trials / Drug Trials email to a friend printer friendly view / write opinions rate article Current Article Ratings: Patient / Public: Health Professional: Article Opinions: XenoPort, Inc.(Nasdaq:XNPT) announced...
|
|
|
XenoPort Reports Positive Results From Arbaclofen Placarbil Trial
For the treatment of patients with spasticity due to spinal cord injury Suppliers to this Sector The Health Protection Agency exists to help protec ...From the control room to the downstream processing ... Independent QA for...
|
|
|
Progressive spastic paraplegia: the combination of Scheuermann's disease, a short-segmented kyphosis and dyspl
1Department of Spine Surgery and Spinal Cord Injury Center, Orthopaedic University Hospital Heidelberg, Heidelberg, Germany 2Department of Radiology, Orthopaedi Progressive spastic paraplegia: the combination of Scheuermann's disease,...
|
|
|
Neuralstem Raises $1 Million in Registered Direct Offering
Vicis Capital Managing Director Chris Phillips stated, We are very excited to complete this transaction as we believe this is a strong investment for our portfolio.We are confident in the company's leadership position to treat...
|
|
|
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients
- XenoPort, Inc.(Nasdaq:XNPT) announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury ...
|
|
|
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients
Companies mentioned in this article: XenoPort, Inc.SANTA CLARA, Calif. -- (BUSINESSWIRE) -- XenoPort, Inc. (Nasdaq:XNPT) announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also...
|
|
|
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients
XenoPort, Inc.(Nasdaq:XNPT) announced today positive preliminary results from a Phase 2 clinical trial of arbaclofen placarbil (AP), also known as XP19986, for the treatment of patients with spasticity due to spinal cord injury (SCI...
|
|
|
XenoPort Reports Positive Results from a Phase 2 Trial of Arbaclofen Placarbil in Spinal Cord Injury Patients
Currently available medications for treating spasticity are often limited by their short duration of action and significant central nervous system side effects, said David A.Stamler, M.D., XenoPort's chief medical officer. The...
|
|
|
Neuralstem Enters into Agreement with China Medical University in Taiwan to Develop Stem Cell Stroke Treatment
We are excited to be moving forward in treating stroke with our cells, said Richard Garr, Neuralstem President & CEO.The preclinical program, which we expect will take between nine months to a year, will focus on qualifying our...
|
|
|
FDA confiscates 33 drugs from Caraco
The U.S.has confiscated 33 generic drugs and raw ingredients at three facilities in metro Detroit. The seizure, which involved inventory of as much as $20 million, occurred Thursday at the company's plants in Detroit, Farmington Hills...
|
|
|
FDA confiscates 33 drugs from Caraco: Raw ingredients also removed from 3 sites [Detroit Free Press]
27--The U.S.Food and Drug Administration has confiscated 33 generic drugs and raw ingredients at three Caraco Pharmaceutical Laboratories facilities in metro Detroit. The seizure, which involved inventory of as much as $20 million,...
|
|
|
FDA confiscates 33 drugs from Caraco
The U.S.has confiscated 33 generic drugs and raw ingredients at three facilities in metro Detroit. The seizure, which involved inventory of as much as $20 million, occurred Thursday at the company's plants in Detroit, Farmington Hills...
|
|
|
FDA confiscates 33 drugs from Caraco
Raw ingredients also removed from 3 sites The U.S.Food and Drug Administration has confiscated 33 generic drugs and raw ingredients at three Caraco Pharmaceutical Laboratories facilities in metro Detroit. The seizure, which involved...
|
|
|
Generic drugs seized from labs in metro Detroit [Detroit Free Press]
26--The U.S.Food and Drug Administration has seized 33 generic drugs and ingredients, an inventory of as much as $20 million at three Caraco Pharmaceutical Laboratories in metro Detroit. The seizure Thursday occurred at the company&...
|
|
|
Medtronic Announces Two Worldwide Clinical Trials To Study Medical Device Interventions For Stroke
Each year, approximately 795,000 people experience a new or recurrent stroke1 in the United States, and approximately a half million people in Western Europe are similarly afflicted2.Today, Medtronic, Inc. (NYSE: MDT) announces two...
|
|
|
Medtronic Announces Two Worldwide Clinical Trials to Study Medical Device Interventions for Stroke
people experience a new or recurrent stroke1 in the United States, and approximately a half million people in Western Europe are similarly afflicted2.Today, Medtronic, Inc. (NYSE: MDT) announces two significant clinical trials related...
|
|
|
Pharming gets Dutch govt grant to develop human lactoferrin for IBD
Biotech company Pharming Group NV (Pharming) has initiated a two-year Food & Nutrition Delta (FND) innovation project to further develop human lactoferrin (hLF) as a nutritional product to manage inflammatory bowel diseases (IBD).The...
|
|
|
Marijuana treatment for H1N1, Diabetes, and MS - it is true
Two companies are doing research on the multivariate uses of cannabis sativa -- marijuana.This is serious research, done correctly, and taken seriously by the medical and research community. Cannabis Science Inc., is studying the...
|
|
|
Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing FDA Assigns Prio
HAWTHORNE, N.Y.--(BUSINESS WIRE)--May.6, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Fampridine-SR New Drug Application (NDA) for filing, assigning...
|
|
|
Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in Peo
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr.23, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the resubmission of its New Drug Application (NDA) for Fampridine-SR to the U.S. Food and Drug Administration (FDA).
|
|
|
XenoPort to Present at the Piper Jaffray Fourth Annual Europe Conference
- XenoPort, Inc.(Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Piper Jaffray Fourth Annual Europe Conference. The live presentation will occur at 5:00 a.m. Pacific Daylight...
|
|
|
CeNeRx BioPharma completes USD9m financing
CeNeRx BioPharma, a clinical stage company developing treatments for diseases of the central nervous system, has completed a USD9m financing.The financing includes a USD5m credit facility from MidCap Financial and an additional USD4m...
|
|
|
Study data from Roessingh Research and Development BV update knowledge of spinal cord injury
Today's Medical & Research News Research findings, 'Perception of lower limb spasticity in patients with spinal cord injury,' are discussed in a new report.'Cross-sectional study. To study the manifestation of ...
|
|
|
CeNeRx BioPharma injects $9M financing
RESEARCH TRIANGLE PARK, NC - CeNeRx BioPharma Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system, has closed a $9 million financing.The financing includes a $5...
|
|
|
MidCap Financial Provides Credit Facility to CeNeRx BioPharma
CeNeRx BioPharma, a clinical stage company that commercializes treatments for diseases of the central nervous system (CNS), said it has completed a $9 million financing.The financing includes a $5 million credit facility from MidCap...
|
